These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 14730339)

  • 1. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma.
    Powell JL; Bunin NJ; Callahan C; Aplenc R; Griffin G; Grupp SA
    Bone Marrow Transplant; 2004 Mar; 33(6):651-7. PubMed ID: 14730339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation.
    Lucas KG; Burton RL; Zimmerman SE; Wang J; Cornetta KG; Robertson KA; Lee CH; Emanuel DJ
    Blood; 1998 May; 91(10):3654-61. PubMed ID: 9573001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
    van Esser JW; Niesters HG; van der Holt B; Meijer E; Osterhaus AD; Gratama JW; Verdonck LF; Löwenberg B; Cornelissen JJ
    Blood; 2002 Jun; 99(12):4364-9. PubMed ID: 12036863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
    van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
    Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood.
    Ohga S; Ishimura M; Yoshimoto G; Miyamoto T; Takada H; Tanaka T; Ohshima K; Ogawa Y; Imadome K; Abe Y; Akashi K; Hara T
    J Clin Virol; 2011 May; 51(1):31-7. PubMed ID: 21377409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease.
    Meij P; van Esser JW; Niesters HG; van Baarle D; Miedema F; Blake N; Rickinson AB; Leiner I; Pamer E; Lowenberg B; Cornelissen JJ; Gratama JW
    Blood; 2003 Jun; 101(11):4290-7. PubMed ID: 12576337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical epidemiology of Epstein-Barr virus-associated Lymphoproliferative Disorders (EBV-LPDs) in hospitalized children: A six-year multi-institutional study in China.
    Dilmurat D; Wang X; Gao L; Tian J; Ai J; Zhang L; Liu M; Feng G; Zeng Y; Wang R; Xie Z
    Ital J Pediatr; 2024 Jul; 50(1):125. PubMed ID: 38956696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and pathological features of 13 children with Epstein-Barr virus-positive lymphoproliferative disease].
    Chen TM; Deng ZJ; Hu B; Hu HL; Chen HY; Li SY; Liu G
    Zhonghua Er Ke Za Zhi; 2018 Oct; 56(10):759-764. PubMed ID: 30293280
    [No Abstract]   [Full Text] [Related]  

  • 11. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
    Awaya N; Adachi A; Mori T; Kamata H; Nakahara J; Yokoyama K; Yamada T; Kizaki M; Sakamoto M; Ikeda Y; Okamoto S
    Leuk Res; 2006 Aug; 30(8):1059-62. PubMed ID: 16330097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation.
    van Esser JW; Niesters HG; Thijsen SF; Meijer E; Osterhaus AD; Wolthers KC; Boucher CA; Gratama JW; Budel LM; van der Holt B; van Loon AM; Löwenberg B; Verdonck LF; Cornelissen JJ
    Br J Haematol; 2001 Jun; 113(3):814-21. PubMed ID: 11380475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes.
    Pakakasama S; Eames GM; Morriss MC; Huls MH; Rooney CM; Heslop HE; Krance RA
    Transplantation; 2004 Sep; 78(5):755-7. PubMed ID: 15371682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disorders.
    Park S; Ko YH
    J Dermatol; 2014 Jan; 41(1):29-39. PubMed ID: 24438142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
    Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
    Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning.
    Cohen J; Gandhi M; Naik P; Cubitt D; Rao K; Thaker U; Davies EG; Gaspar HB; Amrolia PJ; Veys P
    Br J Haematol; 2005 Apr; 129(2):229-39. PubMed ID: 15813851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation.
    Cohen JM; Sebire NJ; Harvey J; Gaspar HB; Cathy C; Jones A; Rao K; Cubitt D; Amrolia PJ; Davies EG; Veys P
    Blood; 2007 Sep; 110(6):2209-14. PubMed ID: 17502458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation.
    Crippa F; Holmberg L; Carter RA; Hooper H; Marr KA; Bensinger W; Chauncey T; Corey L; Boeckh M
    Biol Blood Marrow Transplant; 2002; 8(5):281-9. PubMed ID: 12064366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.